Advanced

CGRP blockers in migraine therapy: where do they act?

Edvinsson, Lars LU (2008) In British Journal of Pharmacology 155. p.967-969
Abstract
Calcitonin gene-related peptide (CGRP) is expressed throughout the CNS and peripheral nervous system, consistent with control of vasodilatation, nociception, motor function, secretion and olfaction. alphaCGRP is prominently localized in primary afferent C and Adelta fibres of spinal and trigeminal ganglia. Activation of the trigeminal nerve results in antidromic release of CGRP, acting through a CGRP1 receptor. Antagonists of CGRP1 receptors reduce signalling in the trigeminovascular pathway at multiple sites, putatively inside the blood-brain barrier. Other ways of interacting with CGRP mechanisms have appeared limiting the availability of CGRP in the circulation with a specific CGRP antibody or with a CGRP-binding RNA-Spiegelmer. Either... (More)
Calcitonin gene-related peptide (CGRP) is expressed throughout the CNS and peripheral nervous system, consistent with control of vasodilatation, nociception, motor function, secretion and olfaction. alphaCGRP is prominently localized in primary afferent C and Adelta fibres of spinal and trigeminal ganglia. Activation of the trigeminal nerve results in antidromic release of CGRP, acting through a CGRP1 receptor. Antagonists of CGRP1 receptors reduce signalling in the trigeminovascular pathway at multiple sites, putatively inside the blood-brain barrier. Other ways of interacting with CGRP mechanisms have appeared limiting the availability of CGRP in the circulation with a specific CGRP antibody or with a CGRP-binding RNA-Spiegelmer. Either way reduces neurogenic inflammation and attenuates signalling within the trigeminovascular pathway. Specific CGRP receptor blockade has been shown to reduce the effect of released CGRP and to abort acute migraine attacks. The novel approach of reducing available CGRP is limited by the blood-brain barrier; its usefulness may be more as prophylaxis rather than as acute treatment of migraine.British Journal of Pharmacology advance online publication, 8 September 2008; doi:10.1038/bjp.2008.346. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
British Journal of Pharmacology
volume
155
pages
967 - 969
publisher
The British Pharmacological Society
external identifiers
  • WOS:000261220700001
  • PMID:18776915
  • Scopus:56749157338
ISSN
1476-5381
DOI
10.1038/bjp.2008.346
language
English
LU publication?
yes
id
58b11a7f-95fa-4e94-9716-3cc44fa41ee7 (old id 1243279)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/18776915?dopt=Abstract
date added to LUP
2008-10-07 13:26:27
date last changed
2016-10-13 04:30:40
@misc{58b11a7f-95fa-4e94-9716-3cc44fa41ee7,
  abstract     = {Calcitonin gene-related peptide (CGRP) is expressed throughout the CNS and peripheral nervous system, consistent with control of vasodilatation, nociception, motor function, secretion and olfaction. alphaCGRP is prominently localized in primary afferent C and Adelta fibres of spinal and trigeminal ganglia. Activation of the trigeminal nerve results in antidromic release of CGRP, acting through a CGRP1 receptor. Antagonists of CGRP1 receptors reduce signalling in the trigeminovascular pathway at multiple sites, putatively inside the blood-brain barrier. Other ways of interacting with CGRP mechanisms have appeared limiting the availability of CGRP in the circulation with a specific CGRP antibody or with a CGRP-binding RNA-Spiegelmer. Either way reduces neurogenic inflammation and attenuates signalling within the trigeminovascular pathway. Specific CGRP receptor blockade has been shown to reduce the effect of released CGRP and to abort acute migraine attacks. The novel approach of reducing available CGRP is limited by the blood-brain barrier; its usefulness may be more as prophylaxis rather than as acute treatment of migraine.British Journal of Pharmacology advance online publication, 8 September 2008; doi:10.1038/bjp.2008.346.},
  author       = {Edvinsson, Lars},
  issn         = {1476-5381},
  language     = {eng},
  pages        = {967--969},
  publisher    = {ARRAY(0x85dc090)},
  series       = {British Journal of Pharmacology},
  title        = {CGRP blockers in migraine therapy: where do they act?},
  url          = {http://dx.doi.org/10.1038/bjp.2008.346},
  volume       = {155},
  year         = {2008},
}